De-repressing LncRNA-targeted genes to upregulate gene expression: Focus on small molecule therapeutics

Roya Pedram Fatemi, Dmitry Velmeshev, Mohammad A Faghihi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Non-protein coding RNAs (ncRNAs) make up the overwhelming majority of transcripts in the genome and have recently gained attention for their complex regulatory role in cells, including the regulation of protein-coding genes. Furthermore, ncRNAs play an important role in normal development and their expression levels are dysregulated in several diseases. Recently, several long noncoding RNAs (lncRNAs) have been shown to alter the epigenetic status of genomic loci and suppress the expression of target genes. This review will present examples of such a mechanism and focus on the potential to target lncRNAs for achieving therapeutic gene upregulation by de-repressing genes that are epigenetically silenced in various diseases. Finally, the potential to target lncRNAs, through their interactions with epigenetic enzymes, using various tools, such as small molecules, viral vectors and antisense oligonucleotides, will be discussed. We suggest that small molecule modulators of a novel class of drug targets, lncRNA-protein interactions, have great potential to treat some cancers, cardiovascular disease, and neurological disorders.

Original languageEnglish (US)
Pages (from-to)e196
JournalMolecular Therapy - Nucleic Acids
Volume3
DOIs
StatePublished - 2014

Fingerprint

Long Noncoding RNA
Up-Regulation
Gene Expression
Untranslated RNA
Epigenomics
Genes
Antisense Oligonucleotides
Therapeutics
Nervous System Diseases
Proteins
Cardiovascular Diseases
Genome
Enzymes
Pharmaceutical Preparations
Neoplasms

Keywords

  • Cancer
  • Cardiovascular disease
  • Epigenetics
  • Gene upregulation
  • Long intervening RNAs
  • Long noncoding RNA
  • Natural antisense transcript
  • Neurological disorders
  • Protein-RNA interactions
  • RNA structure

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

De-repressing LncRNA-targeted genes to upregulate gene expression : Focus on small molecule therapeutics. / Fatemi, Roya Pedram; Velmeshev, Dmitry; Faghihi, Mohammad A.

In: Molecular Therapy - Nucleic Acids, Vol. 3, 2014, p. e196.

Research output: Contribution to journalArticle

@article{6cbe209d3eba4be182f09465fab33f0d,
title = "De-repressing LncRNA-targeted genes to upregulate gene expression: Focus on small molecule therapeutics",
abstract = "Non-protein coding RNAs (ncRNAs) make up the overwhelming majority of transcripts in the genome and have recently gained attention for their complex regulatory role in cells, including the regulation of protein-coding genes. Furthermore, ncRNAs play an important role in normal development and their expression levels are dysregulated in several diseases. Recently, several long noncoding RNAs (lncRNAs) have been shown to alter the epigenetic status of genomic loci and suppress the expression of target genes. This review will present examples of such a mechanism and focus on the potential to target lncRNAs for achieving therapeutic gene upregulation by de-repressing genes that are epigenetically silenced in various diseases. Finally, the potential to target lncRNAs, through their interactions with epigenetic enzymes, using various tools, such as small molecules, viral vectors and antisense oligonucleotides, will be discussed. We suggest that small molecule modulators of a novel class of drug targets, lncRNA-protein interactions, have great potential to treat some cancers, cardiovascular disease, and neurological disorders.",
keywords = "Cancer, Cardiovascular disease, Epigenetics, Gene upregulation, Long intervening RNAs, Long noncoding RNA, Natural antisense transcript, Neurological disorders, Protein-RNA interactions, RNA structure",
author = "Fatemi, {Roya Pedram} and Dmitry Velmeshev and Faghihi, {Mohammad A}",
year = "2014",
doi = "10.1038/mtna.2014.45",
language = "English (US)",
volume = "3",
pages = "e196",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - De-repressing LncRNA-targeted genes to upregulate gene expression

T2 - Focus on small molecule therapeutics

AU - Fatemi, Roya Pedram

AU - Velmeshev, Dmitry

AU - Faghihi, Mohammad A

PY - 2014

Y1 - 2014

N2 - Non-protein coding RNAs (ncRNAs) make up the overwhelming majority of transcripts in the genome and have recently gained attention for their complex regulatory role in cells, including the regulation of protein-coding genes. Furthermore, ncRNAs play an important role in normal development and their expression levels are dysregulated in several diseases. Recently, several long noncoding RNAs (lncRNAs) have been shown to alter the epigenetic status of genomic loci and suppress the expression of target genes. This review will present examples of such a mechanism and focus on the potential to target lncRNAs for achieving therapeutic gene upregulation by de-repressing genes that are epigenetically silenced in various diseases. Finally, the potential to target lncRNAs, through their interactions with epigenetic enzymes, using various tools, such as small molecules, viral vectors and antisense oligonucleotides, will be discussed. We suggest that small molecule modulators of a novel class of drug targets, lncRNA-protein interactions, have great potential to treat some cancers, cardiovascular disease, and neurological disorders.

AB - Non-protein coding RNAs (ncRNAs) make up the overwhelming majority of transcripts in the genome and have recently gained attention for their complex regulatory role in cells, including the regulation of protein-coding genes. Furthermore, ncRNAs play an important role in normal development and their expression levels are dysregulated in several diseases. Recently, several long noncoding RNAs (lncRNAs) have been shown to alter the epigenetic status of genomic loci and suppress the expression of target genes. This review will present examples of such a mechanism and focus on the potential to target lncRNAs for achieving therapeutic gene upregulation by de-repressing genes that are epigenetically silenced in various diseases. Finally, the potential to target lncRNAs, through their interactions with epigenetic enzymes, using various tools, such as small molecules, viral vectors and antisense oligonucleotides, will be discussed. We suggest that small molecule modulators of a novel class of drug targets, lncRNA-protein interactions, have great potential to treat some cancers, cardiovascular disease, and neurological disorders.

KW - Cancer

KW - Cardiovascular disease

KW - Epigenetics

KW - Gene upregulation

KW - Long intervening RNAs

KW - Long noncoding RNA

KW - Natural antisense transcript

KW - Neurological disorders

KW - Protein-RNA interactions

KW - RNA structure

UR - http://www.scopus.com/inward/record.url?scp=84925235630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925235630&partnerID=8YFLogxK

U2 - 10.1038/mtna.2014.45

DO - 10.1038/mtna.2014.45

M3 - Article

AN - SCOPUS:84925235630

VL - 3

SP - e196

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -